form8k5222008.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) May 20,
2008
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
777 Old Saw Mill River
Road, Tarrytown, New York
|
|
10591
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number,
including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section
5 – Corporate Governance and Management
Item
5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b) On
May 20, 2008, Alton B. Kremer, M.D., Ph.D., resigned as Senior Vice President,
Clinical Research of the Company to pursue other interests.
Section 8 – Other
Events
Item
8.01. Other Events.
Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), today announced preliminary findings from two clinical trials
conducted with investigational oral and intravenous formulations of RELISTOR™
(methylnaltrexone bromide). The first of these studies, a phase 2 trial,
evaluated the effects of an oral formulation of RELISTOR for the treatment of
opioid-induced constipation (OIC), in patients with chronic, non-malignant pain.
This study showed positive activity. The second study, a phase 3 trial, examined
the use of an intravenous formulation of RELISTOR for post-operative ileus
(POI). In this study, the drug did not meet its primary or secondary end
points.
A copy of
Progenics’ press release is attached hereto as Exhibit 99.1 and the information
contained therein is incorporated by reference into this Item 8.01 of this
Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. Description
99.1
Press
Release dated May 22, 2008
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A.
McKinney
Chief Financial Officer, Senior Vice President,
Finance & Operations and Treasurer
Date: May 22,
2008